Provider review
Is Pomegranate Health legitimate? Start with these checks
Facility language does not make a compounded medicine FDA-approved. A sourced guide to the care arrangement, complete cost, terms, and contact routes.
Document research · No independent medical review claimedOn this page
Facility language does not make a compounded medicine FDA-approved. That is the starting point for Panda Bear’s look at Pomegranate Health: a specific question to resolve before turning an online offer into a purchase.
We read the provider’s public documents alongside relevant official guidance. This file explains what those materials establish and what still needs an answer. It is not a first-hand patient testimonial, a license audit of every professional, or a promise about an individual treatment.
Who provides the care?
Pomegranate Health describes remote assessment and pharmacy shipment. FDA-related wording about suppliers should be read alongside its disclosure that compounded products themselves have not received FDA review or approval.
Before enrollment, ask which medical practice takes responsibility for assessment and how its clinicians can be reached afterward. The business operating a website and the business making a medical decision may be different. Record both names rather than asking one support team to answer every kind of question.
What belongs in the full bill?
A compounded-semaglutide offer starts at $119 monthly, with care and delivery described as included and no separate membership fee. Confirm which duration and eligibility conditions produce that figure.
Put the charge due today beside the period it covers. Then record the normal renewal and anything collected by a pharmacy or testing service. An unknown charge should remain a question mark in the budget. Our full-cost worksheet keeps those details together.
Which terms deserve a closer look?
The relevant pharmacy check uses the actual dispenser’s legal name and applicable state license. A broad facility description is neither a finished-product approval nor verification of your own order.
Keep the version of the agreement accepted at checkout. If a reply refers to a different promotion, product, or account stage, ask the provider to identify the applicable clause. The cancellation guide distinguishes stopping renewal from stopping pharmacy work and obtaining a refund.
What exactly would be prescribed?
Ask the professional to name the finished medicine, its route, and its dispensing pharmacy. Compounded preparations have not received FDA approval. A claim about an approved medicine or a facility does not establish that a different preparation has the same evidence or approval status.
Prescribing and monitoring depend on the individual assessment. This document review does not test a product, inspect an individual pharmacy order, or decide what treatment you should receive. Use the product-status explanation to prepare questions for that discussion.
Where can you ask for help?
The reviewed documents did not establish a general patient-support phone number or email for this file. A missing number is left unfilled; it is not replaced with an address guessed from the company name.
Reach the official Pomegranate Health website directly to locate the secure patient system. Panda Bear does not manage provider accounts, verify login credentials, or measure support response times.
One question worth taking with you
Which pharmacy will dispense the prescription, and what is the ordinary renewal price for the selected term?
Ask for an answer that names your intended program, rather than a general statement about the company. Save the reply with the proposed prescription and quote. If an important detail remains unresolved, our review leaves that uncertainty visible rather than filling it with a rating.
Trace the information
Sources & research notes
Provider documents describe the provider’s own offer. Official medical references explain context; they do not endorse this publication or its featured partner.
- Pomegranate Health: official program, pricing, and care details Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs Regulatory / public agency · Checked September 22, 2026
Use this guide to prepare questions, not to choose or change a prescription without clinical advice. Research method · Commercial disclosure